Lexeo Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Lexeo Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue0.00-0.530.651.660.52
Cost of Revenue0.0053.1349.1645.124.32
Gross Profit0.00-0.53-48.51-43.46-3.80
Operating Expenses
Research & Development74.0953.1349.1645.120.00
Selling, General & Administrative31.6815.3812.007.170.79
Operating Expenses105.7768.5161.1652.290.79
Operating Income-105.77-68.51-60.51-50.64-4.59
Other Income/Expense
Interest Income7.562.871.330.020.00
Interest Expense0.110.210.090.00-0.15
Other Income/Expense7.430.010.000.000.00
Income
Income Before Tax-98.33-66.39-59.28-50.62-5.15
Income Tax Expense0.000.000.000.000.00
Net Income-98.33-66.39-59.28-50.62-5.15
Net Income - Continuous Operations-98.33-66.39-59.28-50.620.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-96.19-64.38-58.04-50.610.00
EBIT-98.21-66.22-59.19-50.62-4.59
Depreciation & Amortization2.001.841.150.010.00
Earnings Per Share
Basic EPS-3.00-12.00-2.00-2.00-4.00
Diluted EPS-3.00-12.00-2.00-2.00-4.00
Basic Shares Outstanding31.795.3525.1725.171.44
Diluted Shares Outstanding31.795.3525.1725.171.44